Navigation Links
Go figure: Math model may help researchers with stem cell, cancer therapies
Date:1/20/2011

The difficult task of sorting and counting prized stem cells and their cancer-causing cousins has long frustrated scientists looking for new ways to help people who have progressive diseases.

But in a development likely to delight math teachers, University of Florida researchers have devised a series of mathematical steps that accomplishes what the most powerful microscopes, high-throughput screening systems and protein assays have failed to do assess how rapidly stem cells and their malignant, stemlike alter egos increase their numbers.

The method, published in the online journal PLoS ONE in January, may rev up efforts to develop stem cell therapies for Alzheimer's, Parkinson's and other diseases. It may also help get to the root of the cancer-stem cell theory, which puts forth the idea that a tiny percentage of loner cancer cells gives rise to tumors.

"Math is going to be the new microscope of the 21st century because it is going to allow us to see things in biology that we cannot see any other way," said Brent Reynolds, Ph.D., an associate professor of neurosurgery at UF's McKnight Brain Institute and a member of the UF Shands Cancer Center. "Stem cells and the cells that drive cancer may be as infrequent as one in 10,000 or one in 100,000 cells. The problem is how do you understand the biology of something whose frequency is so low?"

Inspired by a 2004 essay by Joel E. Cohen, Ph.D., of The Rockefeller University and Columbia University that described the explosive synergy between mathematics and biology, Reynolds and postdoctoral associate Loic P. Deleyrolle set out to build an algorithm that could determine the rate stem cells and cancer stem cells divide.

High hopes to treat or prevent diseases have been pinned on these indistinguishable cells, which are often adrift in populations of millions of other cells. Scientists know stem cells exist mainly because their handiwork is everywhere tissues heal and regenerate because of stem cells, and somehow cancer may reappear years after it was thought to be completely eliminated.

With Geoffrey Ericksson, Ph.D., a computational neuroscientist at the Queensland Brain Institute, and other scientists in Australia, the team proposed a mathematical interpretation of neurospheres tiny collections of brain cells that include stem cells and their progeny at different stages of development.

They tested the mathematical approach by using brain tumor and breast tumor cells in cultures and in mice, correlating the estimates generated by the mathematical model with the aggressiveness of the cells they were studying.

"The unique thing about our study is we were able to do the biology," Deleyrolle said. "We took our simulation to the real world with real cells."

By offering a method to evaluate the effects of diseases and treatments on stem cell activity in the brain, as well as allowing the assessment of malignant stemlike cells, researchers believe they can better evaluate potential therapies for diseases.

"Estimating the numbers of stem cells one has in a particular tissue or culture has important implications in the development of therapeutics, including those for brain tumors," said Harley Kornblum, M.D., Ph.D., professor in residence at the Broad Center of Regenerative Medicine and Stem Cell Research at the University of California, Los Angeles, who was not involved with the study. "This method provides a mathematical model that will enable researchers to do just that. Certainly, it will help my own research in these areas a great deal."


'/>"/>

Contact: John Pastor
jdpastor@ufl.edu
352-273-5815
University of Florida
Source:Eurekalert

Related biology news :

1. Penn biophysicists create new model for protein-cholesterol interactions in brain and muscle tissue
2. Models of eel cells suggest electrifying possibilities
3. Anti-cancer drug prevents, reverses cardiovascular damage in mouse model of premature aging disorder
4. Swamping bad cells with good in ALS animal models helps sustain breathing
5. Moderate use averts failure of type 2 diabetes drugs in animal model
6. Multiple sclerosis research charges ahead with new mouse model of disease
7. A model to measure soil health in the era of bioenergy
8. New model predicts hot spots for mercury in fish
9. New movement models tested at the Smithsonian in Panama
10. Cytori reports benefit of adipose-derived regenerative cells in spinal disc model
11. Lifecycles of tropical cyclones predicted in global computer model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... MedNet Solutions , an innovative ... spectrum of clinical research, is proud to announce ... the organization in terms of corporate growth, outside ... and services. The company,s exceptional achievements can be ... iMedNet ™ – MedNet,s ...
(Date:1/12/2017)... 12, 2017  New research undertaken by Fit Small ... future.  1,000 participants were simply asked which office technology had ... may consider standard issue.  Insights on what will ... gathered from futurists and industry leaders including Penelope Trunk ... .  Some of these findings ...
(Date:1/11/2017)... , Jan. 11, 2017  Michael Johnson, co-founder of Visikol Inc. ... Group, Inc., has been named to the elite "Forbes 30 Under ... one of 600 people in 20 fields nationwide to be recognized ... the 15,000 applicants were selected. ... He is currently a PhD candidate at Rutgers University. ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... 2017 /PRNewswire -- WuXi AppTec, a leading global ... technology platform, today announced that it has acquired ... drug discovery contract research organization (CRO). After completion ... subsidiary of WuXi, and will continue to focus ... services. The acquisition will further strengthen WuXi,s R&D ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... research and development (R&D), today announced the launch of Data Science ... for the rapidly evolving field of precision medicine. , Data Science ...
(Date:1/19/2017)... and GAITHERSBURG, Md. , Jan. ... and Altimmune, Inc., a privately-held immunotherapeutics company targeting ... definitive agreement for the merger of PharmAthene and ... include Novartis Venture Fund, HealthCap, Truffle Capital and ... fully-integrated and diversified immunotherapeutics company with four clinical ...
(Date:1/19/2017)... 19, 2017 AquaBounty Technologies, Inc. (AIM: ABTU; ... in aquaculture and a majority-owned subsidiary of Intrexon Corporation ... completed the listing of its common shares on the ... Intrexon. "AquaBounty,s listing on NASDAQ represents an ... exposure to the U.S. markets as we advance plans ...
Breaking Biology Technology: